RENAL AND BONE SAFETY OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE

被引:0
|
作者
Post, Frank [1 ]
Sax, Paul [2 ]
Saag, Michael [3 ]
Yin, Michael [4 ]
Oka, Shinichi [5 ]
Koenig, Ellen [6 ]
Trottier, Benoit [7 ]
Andrade, Jaime [8 ]
Cao, Huyen [9 ]
Fordyce, Marshall [9 ]
机构
[1] Kings Coll Hosp London, London, England
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Alabama, Tuscaloosa, AL 35487 USA
[4] Columbia Univ, New York, NY USA
[5] Int Med Ctr Japan, Tokyo, Japan
[6] Dominican Inst Virol Studies, Santo Domingo, Japan
[7] Clin Med Actuel Montreal, Montreal, Dominican Rep
[8] Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico
[9] Gilead Sci Inc, Foster City, Mexico
关键词
D O I
10.1136/sextrans-2015-052126.142
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
P99
引用
收藏
页码:A48 / +
页数:2
相关论文
共 50 条
  • [11] Safety of tenofovir alafenamide (TAF) in patients with a history of proximal renal tubulopathy on tenofovir disoproxil fumarate (TDF)
    Hamzah, L.
    Jones, R.
    Bailey, A.
    Williams, D.
    Johnson, M.
    Ibrahim, F.
    Musso, C.
    Burling, K.
    Campbell, L.
    Post, F.
    HIV MEDICINE, 2019, 20 : 8 - 9
  • [12] Safety of Tenofovir Alafenamide in People With HIV Who Experienced Proximal Renal Tubulopathy on Tenofovir Disoproxil Fumarate
    Campbell, Lucy
    Barbini, Birgit
    Burling, Keith
    Cromarty, Ben
    Hamzah, Lisa
    Johnson, Margaret
    Jones, Rachael
    Samarawickrama, Amanda
    Williams, Deborah
    Winston, Alan
    Post, Frank A.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 88 (02) : 214 - 219
  • [13] Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF)
    De Clercq, Erik
    BIOCHEMICAL PHARMACOLOGY, 2016, 119 : 1 - 7
  • [14] Is Tenofovir Alafenamide Safer than Tenofovir Disoproxil Fumarate for the Kidneys?
    Aloy, Blandine
    Tazi, Imane
    Bagnis, Corinne Isnard
    Gauthier, Marion
    Janus, Nicolas
    Launay-Vacher, Vincent
    Deray, Gilbert
    Tourret, Jerome
    AIDS REVIEWS, 2016, 18 (04) : 184 - 192
  • [15] Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
    Funderburg, Nicholas T.
    McComsey, GraceA.
    Kulkarni, Manjusha
    Bannerman, Tammy
    Mantini, Jessica
    Thornton, Bernadette
    Liu, Hui C.
    Zhang, Yafeng
    Song, Qinghua
    Fang, Liang
    Dinoso, Jason
    Cheng, Andrew
    McCallister, Scott
    Fordyce, Marshall W.
    Das, Moupali
    EBIOMEDICINE, 2016, 13 : 321 - 327
  • [16] COMPARATIVE SAFETY OF TENOFOVIR DISOPROXIL FUMARATE AND TENOFOVIR ALAFENAMIDE IN CHRONIC HEPATITIS B PATIENTS
    Yu, N. Y.
    Chang, K. C.
    VALUE IN HEALTH, 2020, 23 : S532 - S532
  • [17] Switching from tenofovir disoproxil fumarate to tenofovir alafenamide and hepatic safety: a new paradigm?
    Squillace, N.
    Ricci, E.
    Menzaghi, B.
    Migliorino, G.
    De Socio, G.
    Passerini, S.
    Martinelli, C.
    Mameli, M.
    Maggi, P.
    Falasca, K.
    Cordier, L.
    Celesia, B.
    Salomoni, E.
    Di Biagio, A.
    Pellicano, G.
    Bonfanti, P.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [18] Subjects with renal impairment switching from tenofovir disoproxil fumarate to tenofovir alafenamide have improved renal and bone safety through 48 weeks
    Gupta, Samir
    Pozniak, Anton
    Arribas, Josa
    Post, Frank
    Bloch, Mark
    Gathe, Joseph
    Benson, Paul
    Custodio, Joseph
    Abram, Michael
    Wei, Xuelian
    Cheng, Andrew
    McCallister, Scott
    Fordyce, Marshall
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2015, 18
  • [19] A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
    Wassner, Chanie
    Bradley, Nicole
    Lee, Yuman
    JOURNAL OF THE INTERNATIONAL ASSOCIATION OF PROVIDERS OF AIDS CARE, 2020, 19